ATTR-cardiac amyloidosis (ATTR-CM) is a progressive heart condition often mistaken for normal aging. For years, communication in the category has focused on urgency and decline, leaving patients with ...

GEORGETOWN, Ky., May 28, 2026 /PRNewswire/ -- The ATTR Early-Career Research Forum, an academic colloquium focused on recognizing, inspiring, and equipping US-based physician-scientist fellows and ...

BridgeBio Pharma currently markets the ATTR-CM treatment Attruby, which has been on a strong sales trajectory since its 2024 approval. (iStock/Getty Images Plus) BridgeBio Pharma is teaming up with ...

A retrospective MarketScan commercial and Medicare supplemental cohort (2018–2022) identified 505 tafamidis users, using Vyndamax claims as a surrogate marker for confirmed ATTR-CM. Diagnostic delay ...

Kevin M. Alexander, MD, reflects on ACC data for ATTR-CM and its implications for patient care, stressing that clinical trials and extension analyses show ATTR therapies extend survival, improve ...

In ATTR amyloidosis, a buildup of harmful proteins causes damage to tissues and organs throughout the body, including the heart. Over time, the condition can progress from stage 1, which may cause ...

Why Testing Is Important Hereditary ATTR-CM Risk Family Genetic Testing Genetic Counseling Genetic testing is an important part of the diagnosis process for transthyretin cardiac amyloidosis (ATTR-CM) ...

An artificial intelligence model trained to analyze ECG images identified which patients had ATTR-CM. The model had an area under the receiver operating characteristic curve of 0.83 in a high-risk ...

The risk of ischemic stroke was 5.8% among patients with ATTR-CM and atrial fibrillation using tafamidis compared with 9.4% in patients not using the treatment. Tafamidis treatment was associated with ...

With the increasing diagnosis of transthyretin amyloid cardiomyopathy (ATTR-CM) at earlier stages and new therapies, there is a rising demand for tools to stratify risk and prognosis. We evaluated the ...

Based on market patterns in other diseases such as pulmonary arterial hypertension and atrial fibrillation, Alnylam believes that the entire ATTR-CM category is still in its infancy. (iStock / Getty ...